• CEO Jakob Lindberg on Oncopeptides and Ygalo.

  • Oncopeptides

    Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. The company focus on the development of the lead product candidate Ygalo®, an alkylating peptide, Peptidase Enhanced Compounds (PEnCs). Ygalo® is intended as an effective treatment of hematological cancers, and in particular multiple myeloma.

About Ygalo®

Ygalo®, an alkylating peptide, belongs to a novel class of peptidase-enhanced compounds (PEnCs) and targets the MM tumor transformation process with a unique mechanism of action. Ygalo® differs from current cytotoxics through its unique ability to achieve higher concentrations of cancer killing molecules in cancer cells without a corresponding increase in damage to the patient’s bone marrow. Pre-clinical studies also show that Ygalo® kills on average 50 times more cancer cells than similar classes of treatment.

Jefferies 2018 London Healthcare conference – Presentation & webcast

Oncopeptides CEO Jakob Lindberg held a presentation at Jefferies 2018 Healthcare conference in London November 14. The presentation was also recorded as a webcast.

Mechanism of action

Ygalo®, an alkylating peptide, belongs to a novel class of peptidase-enhanced compounds (PEnCs) and targets the MM tumor transformation process with a unique mechanism of action.

Back to top